Accelerating new treatments for global infectious diseases
Mission – What we do
To synthesize the extraordinary and diverse scientific expertise of CAMM investigators to transform the therapeutics development process, accelerating cures for microbial diseases of public health importance.
Vision – What we will achieve
A new era in which molecular measures of microbial cellular processes guide therapeutics development, enabling faster, smarter, more accurate selection of improved drugs and vaccines that save human lives.
Purpose – Why we do it
To innovate solutions for a key roadblock that holds back therapeutics development: the need for improved measures of therapeutic efficacy.
Recent News
Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice
SEARCH-TB demonstrates potential to be used as a highly granular pharmacodynamic assay that reveals antibiotic effects that are not apparent based on culture alone [Accepted in Antimicrobial Agents and Chemotherapy].
CAMM Investigators in collaboration with the Rapid Research in Diagnostics Development for TB (R2D2) Network launch The Candidate Clinical Correlate as Prognostic Outcome for TB (C3PO) Trial
CAMM Investigators in collaboration with the Rapid Research in Diagnostics Development for TB (R2D2) Network launch The Candidate Clinical Correlate as Prognostic Outcome for TB (C3PO) Trial. C3PO seeks to evaluate predictors of serious post-treatment outcomes among...
CAMM partners with MRI Global and The NIAID Mycobacterium tuberculosis Quality Assurance (TBQA) Program to support the external replication and validation of RS ratio®
CAMM partners with MRI Global and The NIAID Mycobacterium tuberculosis Quality Assurance (TBQA) Program to support the external replication and validation of RS ratio®.